Ropharma Bras (RPH) - Net Assets
Based on the latest financial reports, Ropharma Bras (RPH) has net assets worth RON259.34 Million RON (≈ $59.55 Million USD) as of December 2024. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (RON947.76 Million ≈ $217.62 Million USD) and total liabilities (RON688.42 Million ≈ $158.07 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. See Ropharma Bras (RPH) net asset quality to measure how much of total assets are equity-financed.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | RON259.34 Million |
| % of Total Assets | 27.36% |
| Annual Growth Rate | 10.35% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 9.15 |
Ropharma Bras - Net Assets Trend (2021–2025)
This chart illustrates how Ropharma Bras's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see how much is Ropharma Bras worth.
Annual Net Assets for Ropharma Bras (2021–2025)
The table below shows the annual net assets of Ropharma Bras from 2021 to 2025. Also explore RPH net assets growth trend to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-06-30 | RON259.34 Million ≈ $59.55 Million |
+2.97% |
| 2024-06-30 | RON251.85 Million ≈ $57.83 Million |
+7.86% |
| 2023-06-30 | RON233.49 Million ≈ $53.61 Million |
+26.27% |
| 2022-06-30 | RON184.92 Million ≈ $42.46 Million |
+5.73% |
| 2021-06-30 | RON174.90 Million ≈ $40.16 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Ropharma Bras's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 16.9% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (June 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | RON30.05 Million | 12.26% |
| Other Components | RON215.17 Million | 87.74% |
| Total Equity | RON245.23 Million | 100.00% |
Ropharma Bras Competitors by Market Cap
The table below lists competitors of Ropharma Bras ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Advancecon Holdings Bhd
KLSE:5281
|
$25.36 Million |
|
Carelabs Co.Ltd
KQ:263700
|
$25.36 Million |
|
SDT Uzay ve Savunma Teknolojileri A.S.
IS:SDTTR
|
$25.37 Million |
|
Reyna Silver Corp
V:RSLV
|
$25.37 Million |
|
Helium Evolution Inc
V:HEVI
|
$25.35 Million |
|
TRF Limited
NSE:TRF
|
$25.35 Million |
|
Ktop Reit
KO:145270
|
$25.35 Million |
|
NBEST Prime VIII Inmuebles Socimi SA
MC:YINB8
|
$25.34 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Ropharma Bras's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 240,082,812 to 245,227,946, a change of 5,145,134 (2.1%).
- Net loss of 1,725,895 reduced equity.
- Dividend payments of 4,230,472 reduced retained earnings.
- Other factors increased equity by 11,101,501.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | RON-1.73 Million | -0.7% |
| Dividends Paid | RON4.23 Million | -1.73% |
| Other Changes | RON11.10 Million | +4.53% |
| Total Change | RON- | 2.14% |
Book Value vs Market Value Analysis
This analysis compares Ropharma Bras's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.45x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 0.63x to 0.45x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-06-30 | RON0.34 | RON0.22 | x |
| 2022-06-30 | RON0.36 | RON0.22 | x |
| 2023-06-30 | RON0.45 | RON0.22 | x |
| 2024-06-30 | RON0.47 | RON0.22 | x |
| 2025-06-30 | RON0.48 | RON0.22 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Ropharma Bras utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -0.70%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -0.14%
- • Asset Turnover: 1.26x
- • Equity Multiplier: 3.86x
- Recent ROE (-0.70%) is below the historical average (3.23%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 3.86% | 0.94% | 1.67x | 2.46x | RON-10.74 Million |
| 2022 | 5.80% | 1.38% | 1.82x | 2.31x | RON-7.76 Million |
| 2023 | 3.98% | 1.01% | 1.18x | 3.33x | RON-13.94 Million |
| 2024 | 3.21% | 0.77% | 1.25x | 3.36x | RON-16.29 Million |
| 2025 | -0.70% | -0.14% | 1.26x | 3.86x | RON-26.25 Million |
Industry Comparison
This section compares Ropharma Bras's net assets metrics with peer companies in the Pharmaceutical Retailers industry.
No peer company data available for comparison.
About Ropharma Bras
S.C. Ropharma S.A., together with its subsidiaries, operates a chain of pharmacies in Romania. The company offers medicines on prescription, over-the-counter (OTC) medications, food supplements, dermato-cosmetics, cosmetics, and medical devices, as well as other healthcare products dispensed through pharmacies. It also provides medical services in various areas, including oncology, hematology, on… Read more